ALCAM and ovarian neoplasm: EGFR, in association with other protein molecules (such as phorbol esters and pervanadate), via molecular signals triggered in various pathways, ensures the release of ALCAM from ovarian tumor cells through a metalloproteinases-dependent mechanism, regulated by the proteolytic activity of ADAM17/TACE, which determines the occurrence of sALCAM in ascites and serum [22, 24].